Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation in the 2022 RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 4:35 p.m. ET in New York, NY.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation in the 2022 RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 4:35 p.m. ET in New York, NY. The company's senior management will engage in a fireside chat, with a live webcast available in the Investor section of their website. Karyopharm is noted for pioneering novel cancer therapies, including their lead SINE compound, XPOVIO®, which is approved in several oncology indications. The event will be available for replay for 90 days.
Details
News Market Reaction – KPTI
The recorded move for KPTI in the trading session of this news was +14.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 4:35 p.m. ET in New York, NY.
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®), China and Singapore. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
SOURCE Karyopharm Therapeutics Inc.
View original content:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-2022-rbc-capital-markets-global-healthcare-conference-301542918.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.